Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 70518-3489 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
This is a prescription medicine called Losartan Potassium. There are 30 tablets in the quantity. The recommended storage temperature range is from 20-25°C (88-77°F). It is manufactured by Sclce in Cranbury, NJ with Lot # not available. The NDC number for the product is 70518-3489-00 and the Source NDC is 43547-0360-11. This medication should be kept out of the reach of children. For usage directions, please refer to the Package Insert. Repackaging is done by RemedyRepack Inc. located in Indiana, PA 15701.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
This text appears to be a comparison between two medications, Atenolol and Losartan Potassium, for a primary endpoint related to patient outcomes. The information provided shows an adjusted risk reduction of 13% with a p-value of 0.021. The timeline of the study is also shown, with a duration of 66 months broken down into individual months.*
Figure 2 - spl image3 figure2
The text is describing a comparison between two medications, Atenolol and Losartan Potassium. It states that Losartan Potassium has an adjusted risk reduction of 25% with a p-value of 0.001. The text also provides a table indicating the percentage of patients with fatal/non-fatal strokes at each study month, ranging from 6 to 66 months.*
Figure 3 - spl image4 figure3
This is a table displaying the primary endpoint events within demographic subgroups for patients using Losartan Potassium and Atenolol. The primary composite stroke (fatal/non-fatal) occurrence rate is given as a percentage along with the hazard ratio (95% CI) for each demographic subgroup. The subgroup categories include age, gender, race, ISH, diabetes, and history of CVD. The table also notes that the symbols are proportional to sample size, and the hazard ratios have been adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - spl image5 figure4
This appears to be a graph or table that shows the percentage of patients with an event over time (measured in months) for two treatments, Losartan Potassium and Placebo. The table also states that the Risk Reduction for Losartan Potassium compared to Placebo is 16.1%, and the p-value for this result is 0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.